Here are four notes:
1. The initiative evaluate the effects of obeticholic acid and other product candidates on the microbiome in a number of chronic liver diseases, beginning with nonalcoholic steatohepatitis.
2. University of Pennsylvania’s PennCHOP Microbiome Program is a collaboration between the Perelman School of Medicine at the University of Pennsylvania in Philadelphia and the Children’s Hospital of Philadelphia.
3. PennCHOP will analyze samples from Intercept’s ongoing international Phase 3 REGENERATE trial in NASH patients with fibrosis and evaluate how OCA influences the composition and activity of the resident microbiota in the gastrointestinal tract.
4. Financial details of the seven-year collaboration will not be disclosed.
More articles on GI/endoscopy:
3 points on the 2016 Gut Microbiota for Health World Summit
Central Illinois Endoscopy Center performs free colonoscopy for veterans
5 key thoughts from Dr. Brian Hudes on GI physician entrepreneurship
